Capricor Therapeutics to Showcase Innovations at Leading Conferences
SAN DIEGO - Capricor Therapeutics, a distinguished biotechnology firm dedicated to transformative therapies, is gearing up to present at several important investor and scientific conferences in the upcoming weeks. Specializing in cell and exosome-based therapeutics for rare diseases, Capricor's participation in these events will highlight its latest advancements.
Upcoming Conference Events
Capricor will take part in several significant conferences where it will share insights on its innovative advancements and future plans. Here are the details of the upcoming presentations:
H.C. Wainwright Annual Global Investment Conference
This conference is set for September 9, 2024, at 2:00 p.m. ET. It will include a company presentation and one-on-one meetings, allowing Capricor to connect with investors and stakeholders.
Annual Exosome-Based Therapeutic Summit
Scheduled for September 17 to 19, 2024, in Boston, this summit is vital for industry leaders. Capricor will participate with a company presentation and an industry panel focused on exosome therapies.
2024 Cantor Fitzgerald’s Global Healthcare Conference
Capricor will also present its progress at this conference on September 18, 2024, at 8:35 a.m. ET, which will feature a fireside chat and one-on-one meetings.
Key Updates on Deramiocel
At these conferences, Capricor's management will provide updates on deramiocel, the company’s flagship product candidate designed for treating Duchenne muscular dystrophy (DMD). Deramiocel (CAP-1002) is advancing through crucial phases of clinical development and has shown promising results in addressing this serious condition.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is committed to advancing cell and exosome-based therapeutics that aim to transform the treatment landscape for rare diseases. Its lead candidate, deramiocel, is a cardiac-derived cell therapy that has demonstrated immunomodulatory, antifibrotic, and regenerative properties through extensive preclinical and clinical studies.
Currently, deramiocel is undergoing Phase 3 clinical trials for DMD, a severe genetic disorder marked by progressive muscle degeneration. The company is also leveraging its proprietary StealthX™ platform to explore exosome technology for targeted delivery of therapies across various diseases.
Capricor remains dedicated to innovating and advancing treatments for patients with unmet medical needs, advocating for their health and well-being. For more information about Capricor's innovative initiatives, please visit their official website at capricor.com.
Frequently Asked Questions
What is the focus of Capricor Therapeutics?
Capricor Therapeutics is focused on developing transformative therapies for rare diseases, particularly through cell and exosome-based therapeutics.
When is Capricor presenting at the H.C. Wainwright Annual Global Investment Conference?
The presentation is scheduled for September 9, 2024, at 2:00 p.m. ET.
What is deramiocel?
Deramiocel (CAP-1002) is Capricor's lead product candidate aimed at treating Duchenne muscular dystrophy, showing promise in clinical development.
Which technologies is Capricor developing?
Capricor is developing its proprietary StealthX™ platform, which utilizes exosome technology for targeted therapeutic delivery.
How can I learn more about Capricor's clinical trials?
To get detailed information about clinical trials and developments, visit Capricor's official website.